BR112017023788A2 - composições de ácido nucleico?polímero catiônico e processo para a preparação de dita composição - Google Patents

composições de ácido nucleico?polímero catiônico e processo para a preparação de dita composição

Info

Publication number
BR112017023788A2
BR112017023788A2 BR112017023788A BR112017023788A BR112017023788A2 BR 112017023788 A2 BR112017023788 A2 BR 112017023788A2 BR 112017023788 A BR112017023788 A BR 112017023788A BR 112017023788 A BR112017023788 A BR 112017023788A BR 112017023788 A2 BR112017023788 A2 BR 112017023788A2
Authority
BR
Brazil
Prior art keywords
nucleic acid
cationic polymer
preparing
composition
polymer compositions
Prior art date
Application number
BR112017023788A
Other languages
English (en)
Portuguese (pt)
Inventor
Hochberg Abraham
GALLULA Jennifer
Original Assignee
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd filed Critical Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Publication of BR112017023788A2 publication Critical patent/BR112017023788A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Manufacturing & Machinery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112017023788A 2015-05-05 2016-05-05 composições de ácido nucleico?polímero catiônico e processo para a preparação de dita composição BR112017023788A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL23864315 2015-05-05
PCT/IL2016/050477 WO2016178233A1 (en) 2015-05-05 2016-05-05 Nucleic acid-cationic polymer compositions and methods of making and using the same

Publications (1)

Publication Number Publication Date
BR112017023788A2 true BR112017023788A2 (pt) 2018-10-16

Family

ID=56134418

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017023788A BR112017023788A2 (pt) 2015-05-05 2016-05-05 composições de ácido nucleico?polímero catiônico e processo para a preparação de dita composição

Country Status (14)

Country Link
US (2) US20180154023A1 (cg-RX-API-DMAC7.html)
EP (1) EP3291799A1 (cg-RX-API-DMAC7.html)
JP (2) JP2018515479A (cg-RX-API-DMAC7.html)
KR (1) KR20180015145A (cg-RX-API-DMAC7.html)
CN (1) CN107735079A (cg-RX-API-DMAC7.html)
AU (1) AU2016258326A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017023788A2 (cg-RX-API-DMAC7.html)
CA (1) CA2984879A1 (cg-RX-API-DMAC7.html)
IL (1) IL255254A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017014060A (cg-RX-API-DMAC7.html)
PH (1) PH12017502216A1 (cg-RX-API-DMAC7.html)
RU (1) RU2017140065A (cg-RX-API-DMAC7.html)
SG (2) SG10201909209RA (cg-RX-API-DMAC7.html)
WO (1) WO2016178233A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3291799A1 (en) * 2015-05-05 2018-03-14 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Nucleic acid-cationic polymer compositions and methods of making and using the same
DE102017003004A1 (de) 2017-03-23 2018-09-27 Friedrich-Schiller-Universität Jena Kationische Polymere mit D-Fructose-Substituenten
JP2020520368A (ja) * 2017-05-17 2020-07-09 ビオンコテック セラピューティクス エセ.エレ 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物
EP3924463A1 (en) 2019-02-11 2021-12-22 Excellgene SA Novel eukaryotic cell transfection systems and related methods
CN111363761A (zh) * 2020-03-17 2020-07-03 苏州吉恒基因科技有限公司 利用阳离子多聚体dna复合物促进aav介导的基因表达方法
JP2023523314A (ja) * 2020-04-27 2023-06-02 ジュノー セラピューティクス インコーポレイテッド ポリエチレンイミン-デオキシリボ核酸複合体のサイズおよび活性の安定化
TW202228727A (zh) * 2020-10-01 2022-08-01 德商拜恩迪克公司 適用於治療之微脂體rna調配物之製備及儲存
US20240245720A1 (en) 2021-05-25 2024-07-25 Ramot At Tel-Aviv University Ltd. Compositions comprising extracellular vesicles and an active agent and uses thereof
CN113501889A (zh) * 2021-07-06 2021-10-15 郑州大学 一种三七多糖阳离子衍生物的制备方法及其应用
CN116549626A (zh) * 2022-01-27 2023-08-08 深圳瑞吉生物科技有限公司 一种载核酸脂质纳米颗粒冻干制剂及其制备方法与应用
CN114762731B (zh) * 2022-05-16 2024-08-23 常州大学 一种延长基因药物在温和条件下储存时间的方法
CN116036043A (zh) * 2023-01-10 2023-05-02 深圳市乐土生物医药有限公司 一种核酸药物制剂、冻干粉及制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
US6087164A (en) * 1997-10-03 2000-07-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
US20040142474A1 (en) * 2000-09-14 2004-07-22 Expression Genetics, Inc. Novel cationic lipopolymer as a biocompatible gene delivery agent
AU2006267841B2 (en) 2005-07-07 2011-12-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid agents for downregulating H19, and methods of using same
EP1926814B1 (en) 2005-09-22 2010-04-28 Yissum Research Development Company, of The Hebrew University of Jerusalem Nucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
EP2111449B1 (en) 2007-01-16 2012-03-07 Yissum Research Development Company of the Hebrew University of Jerusalem H19 silencing nucleic acid agents for treating rheumatoid arthritis
CN107049965A (zh) * 2007-08-06 2017-08-18 Clsn实验室股份有限公司 核酸‑脂聚合物组合物
US20090042825A1 (en) * 2007-08-06 2009-02-12 Majed Matar Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer
BRPI0818937B8 (pt) 2007-10-25 2021-05-25 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd constructos contendo múltiplos cassetes de expressão para terapia de câncer
WO2010028093A2 (en) * 2008-09-03 2010-03-11 Senesco Technologies, Inc. Use of a truncated elf-5a1 polynucleotide to induce apoptosis in cancer cells
DE102009006606A1 (de) * 2009-01-29 2010-08-05 Philipps-Universität Marburg Nicht-virales Transfektionsmittel
EP3291799A1 (en) * 2015-05-05 2018-03-14 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Nucleic acid-cationic polymer compositions and methods of making and using the same

Also Published As

Publication number Publication date
SG10201909209RA (en) 2019-11-28
EP3291799A1 (en) 2018-03-14
WO2016178233A1 (en) 2016-11-10
CA2984879A1 (en) 2016-11-10
US20180154023A1 (en) 2018-06-07
US20200138977A1 (en) 2020-05-07
PH12017502216A1 (en) 2018-06-11
JP2021130671A (ja) 2021-09-09
MX2017014060A (es) 2018-07-06
IL255254A0 (en) 2017-12-31
KR20180015145A (ko) 2018-02-12
JP2018515479A (ja) 2018-06-14
RU2017140065A (ru) 2019-06-05
RU2017140065A3 (cg-RX-API-DMAC7.html) 2019-09-27
CN107735079A (zh) 2018-02-23
AU2016258326A1 (en) 2017-11-23
SG11201708760PA (en) 2017-11-29

Similar Documents

Publication Publication Date Title
PH12017502216A1 (en) Nucleic acid-cationic polymer compositions and methods of making and using the same
AR093377A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
BR112018010585A2 (pt) composições de betume compreendendo lignina
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
BR112016004023A2 (pt) Composição, métodos para preparar uma composição e para tratar uma doença, e, composto
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
BR112015012987A2 (pt) composições compreendendo anticorpos anti-cd38 e lenalidomida
CO7240361A2 (es) Composiciones de arni de serpinc1 y métodos de uso de las mismas
BR112015023752A2 (pt) complexos multiespecificos monovalentes e multivalentes e seus usos
BR112016017261A8 (pt) composto, composição farmacêutica, uso de um composto e processo para a fabricação de um composto
MX2017004039A (es) Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso.
MX2020011415A (es) Metodos de usar zscan4 para rejuvenecer celulas humanas.
MX387994B (es) Derivados de pirazol como moduladores del canal de calcio activado por liberacion de calcio.
ECSP14013132A (es) Anticuerpos anti-psgl-1 y usos de los mismos
BR112015011244A2 (pt) Análogos de compstatina de ação prolongada, método de fabricação e uso dos mesmos, bem como composição de qualidade farmacêutica
BR112016015105A2 (pt) Conjugados var2csa-droga
CY1121859T1 (el) Μεθοδος παρασκευης αναστολεων συνθασης γλυκοζυλοκεραμιδης
BR112017005997A2 (pt) método
EP3037523A4 (en) Production method and cryopreservation method for amniotic mesenchymal cell composition, and therapeutic agent
BR112016024421A2 (pt) composição farmacêutica, cápsula e uso da composição farmacêutica
BR112015018047A8 (pt) método para preparar composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão e as mesmas
BR112017021191A2 (pt) um extrato de indigo naturalis e um processo para preparar o mesmo
BR112015007843A2 (pt) método para a preparação de um polímero, polímero, artigo e método de preparação de um artigo
PE20170147A1 (es) Composiciones de oligonucleotidos y metodos para realizarlas
BR112015002464B8 (pt) processo para a preparação de carbamat-benzoxazinona, carbamat-benzoxazinona e uso da carbamat-benzoxazinona

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements